kreon capsule gastrorezistente 150 mg
abbott laboratories gmbh - pancreatinum - capsule gastrorezistente - 150 mg
kreon capsule gastrorezistente 300 mg
abbott laboratories gmbh - pancreatinum - capsule gastrorezistente - 300 mg
vagiprost 25 mcg ovule
farmaprim srl - misoprostolum - ovule - 25 mcg
venolife gel 2,5 mg (300 ui) + 50 mg + 20 mg/g
akrihin sad, combinat chimico-farmaceutic - heparinum + colecalciferol. resin. + troxerutinum - gel - 2,5 mg (300 ui) + 50 mg + 20 mg/g
venolife gel 2,5 mg (300 ui) + 50 mg + 20 mg/g
akrihin sad, combinat chimico-farmaceutic - heparinum + colecalciferol. resin. + troxerutinum - gel - 2,5 mg (300 ui) + 50 mg + 20 mg/g
wobenzym comprimate gastrorezistente
mucos pharma gmbh&co.kg - o combinatie - comprimate gastrorezistente
aranesp
amgen europe b.v. - darbepoetină alfa - anemia; cancer; kidney failure, chronic - alte preparate antianemice - tratamentul anemiei simptomatice asociate cu insuficiența renală cronică (crf) la adulți și copii. tratamentul anemiei simptomatice la pacienții adulți cu cancer non-mieloid administrează chimioterapie.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
caspofungina mylan 50 mg
pharmadox healthcare, ltd - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice
caspofungina mylan 70 mg
pharmadox healthcare, ltd - malta - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice